Jennifer A. Woyach, MD, Discusses Use of Ibrutinib in CLL at 2021 ASH
Jennifer A. Woyach, MD, spoke about why it’s important to use newer therapies instead of chemoimmunotherapy for patients with chronic lymphocytic leukemia.
Jennifer A. Woyach, MD, on Updated Results of the AO41202 Trial Testing Ibrutinib Regimens in CLL at ASH 2021
Jennifer A. Woyach, MD, spoke about the results of a study conducted in elderly patients treated with an ibrutinib-containing regimen for chronic lymphocytic leukemia at 55 months of follow-up.
Jennifer A. Woyach, MD, Discusses Previous Results of the AO41202 Trial Examining Ibrutinib Regimens in CLL
Jennifer A. Woyach, MD, spoke about the phase 3 AO41202 study, which investigated different ibrutinib regimens for elderly patients with chronic lymphocytic leukemia.
Jennifer A. Woyach, MD, Discusses Exciting Abstracts at ASH 2021
Jennifer A. Woyach, MD, spoke about which abstracts she’s most excited to see presented at the 2021 American Society of Hematology Annual Meeting.
Jennifer A. Woyach, MD, on the Alliance A041702 Trial in Chronic Lymphocytic Leukemia
The Ohio State University Comprehensive Cancer Center expert discussed the ongoing Alliance A041702 trial at the ASH Annual Meeting and Exposition.
COUNTERPOINT: Does Chemoimmunotherapy Still Have a Role in CLL?
Elimination of chemotherapy from our combination regimens should be a shared goal among researchers that will move us a step closer to more patient-friendly and scientifically driven therapies for CLL.